Skip Navigation
 
 
 
 xxx
 
Print This Page
Share this page: More
 

Vered Stearns, M.D.

StearnsCo-director, Breast Cancer Program
Professor of Oncology
Breast Cancer Research Chair in Oncology, Johns Hopkins School of Medicine

Vered Stearns, M.D., became interested in oncology even before she knew what the word meant. When she was 5 years old, she witnessed her grandfather dying of cancer. She decided then that, when she grew up, she wanted to become a doctor and cure cancer. “While my understanding of oncology has obviously grown more sophisticated, I hope never to lose my childhood enthusiasm for improving the welfare of those afflicted with cancer,” Dr. Stearns says.  

During her fellowship, where she first began focusing on breast cancer, Dr. Stearns enjoyed the privilege of working with internationally recognized physician-scientist whom, she recalls, moved seamlessly between the laboratory and clinic. “I was impressed not only with the breadth of their scientific knowledge, but even more so with their ability to translate state-of-the art research into the specific context of patient treatments,” she says.

Dr. Stearns has patterned her own career after these translational physician-scientists. As for her research goals, she aims to further an individualized approach to the prevention, treatment and care for people with or at risk of breast cancer. Already, she has made inroads toward this goal.

Dr. Stearns and her colleagues were the first to evaluate the role of specific cancer-related genetic variants, or mutations, among survivors who had been administered the drug tamoxifen to prevent the re-occurrence of breast cancer. Specifically, they examined the interplay of these genetic mutations in relation to tamoxifen’s metabolism, safety, and efficacy. 

Dr. Stearns and her associates now are applying this same principle to evaluate the association between genetic variants and the outcomes of aromatase inhibitors, a class of drugs used to treat breast cancer in post-menopausal women. By evaluating these genetic variants in study subjects, as well as their responses to surveys (related to treatment symptoms) administered several times a year, she and her co-investigators hope to pinpoint factors that will predict which patients are likely to develop side effects from aromatase inhibitors.

The ongoing explosion of knowledge about the molecular basis of cancer, combined with the generosity of patients who continue to commit their time in clinical trials to further scientists’ understanding of breast cancer, make Dr. Stearns optimistic about the future.  

“Improvements in bioinformatics will give us more pathways to recognize risk, determine prognosis, and estimate benefits from specific treatments,” she says. “It’s really important for individuals to keep an open mind about what clinical trials might be available, and to talk about that with their physicians. Today’s treatment standards are based on yesterday’s clinical trials.”

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer